TriSalus Life SciencesTLSI
About: TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
8% more funds holding
Funds holding: 26 [Q1] → 28 (+2) [Q2]
3.02% more ownership
Funds ownership: 3.56% [Q1] → 6.57% (+3.02%) [Q2]
0% more capital invested
Capital invested by funds: $9.16M [Q1] → $9.21M (+$43.5K) [Q2]
33% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 9
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Oppenheimer Suraj Kalia 61% 1-year accuracy 11 / 18 met price target | 139%upside $10 | Outperform Initiated | 16 Sept 2024 |
Financial journalist opinion
Based on 3 articles about TLSI published over the past 30 days